Good business with its weight core and diabetes funds Ozempic and Wegovy gave the Danish pharmaceutical company Novo Nordisk to Momentum last year. The group hit itself better than expected. Management gives a rather careful prediction for 2025.
In 2024, in the previous year, sales climbed by 25 (adapted in the currency 26) to a good Danish crowns of 290 billion (EUR 38.9 billion), as the group announced in Bagvaerd on Wednesday. The bottom line is that the profit rose by 21 percent to 101 billion crowns. The group therefore exceeded the expectations of analysts, the sale with the much -called weight butcher Wegovy was within the framework of the predictions.
“In 2025 we will continue to concentrate on the commercial implementation, on our early and advanced research frip line and the expansion of production capacities,” said CEO Jørgensen of the announcement.
The turnover increase of up to 26 percent
Novonordisk expects a modified increase of 16 to 24 percent for the new year – that would be 2 percentage points less than 2024, even at the top. Last year, Novonordisk in Dag -Day Business with around 128 billion crowns earned currency -adjusted by 26 percent more than in the previous year.
Source: Krone
I’m Ben Stock, a journalist and author at Today Times Live. I specialize in economic news and have been working in the news industry for over five years. My experience spans from local journalism to international business reporting. In my career I’ve had the opportunity to interview some of the world’s leading economists and financial experts, giving me an insight into global trends that is unique among journalists.
